Company / EPS (Diluted)
Dianthus Therapeutics, Inc. /DE/ EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.55
FY2025
5-year range
-$32.57 / -$1.29
FY2021-FY2025
Trend
+69.8%
vs FY2024
Sector context
#141 of 204
Health Care
What the data says
At $-2.55, Dianthus Therapeutics, Inc. /DE/'s eps (diluted) ranks #141 of 204 in the Health Care sector. Improved from $-8.45 to $-2.55 over the past 2 years.
Based on SEC 10-K filings.
-2.55 in FY2025.
Improved from $-8.45 to $-2.55 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#141 of 204 in Health CareTop 69% of 204This company -$2.55 Sector average -$0.98
▼
-160.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 69.8% year-over-year.
- Ranks #141 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.55 | +69.8% |
| FY2024 | -$8.45 | +0.0% |
| FY2023 | -$8.45 | +74.1% |
| FY2022 | -$32.57 | -2424.8% |
| FY2021 | -$1.29 | +24.6% |
| FY2020 | -$1.71 | +91.1% |
| FY2019 | -$19.12 | +70.7% |
| FY2018 | -$65.15 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026